$0.51
+0.02 (+3.24%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VXRT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
23 interventional · 6 with posted results
Held by 0 tracked-famous managers · FINRA short interest 3.9 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionNCT06672055KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 14 Days Post-vaccinationRandomized · Double-masked · Prevention | Phase 2 | Active, not recruiting | Biological: VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 | SARS-CoV2, COVID-19 | 5,485 | May 2027 | ≤ 285 d | 2026-06-25 |
| A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years OldNCT06944717Number of Participants Experiencing Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) for 1 Week Following Study Intervention DoseNon-randomized · Open-label · Prevention | Phase 1 | Completed | Biological: VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T | Norovirus Infections | 60 | 2026-04-14actual | — | 2026-07-27 |
| A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing InfantsNCT07254728results2026-04-15Number of Participants (Mothers) With Any Solicited Symptoms of Reactogenicity for 1 Week Following Trial DoseRandomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets | Norovirus Infections | 76 | 2024-12-13actual | — | 2026-04-15 |
| A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersNCT05626803results2025-04-15Number of Participants With Solicited Symptoms of Reactogenicity (Gastrointestinal [GI] and Systemic)Randomized · Quadruple-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo | Norovirus Infections | 135 | 2023-10-16actual | — | 2025-04-15 |
| Norovirus Challenge StudyNCT05212168results2025-05-06Number of Participants Who Experienced Norovirus Gastroenteritis (NVG)Randomized · Single-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: VXA-G1.1-NN, Norovirus GI.1 Norwalk Virus Inoculum · Other: Placebo Tablets | Norovirus Infections | 165 | 2023-04-13actual | — | 2025-11-05 |
| A Ph 2 Trial With an Oral Tableted COVID-19 VaccineNCT05067933results2025-04-13Number of Participants Who Experienced a Solicited Symptom of ReactogenicityRandomized · Triple-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study drug was no longer available. | Drug: VXA-CoV2-1.1-S · Other: Placebo Tablets | COVID-19 | 66 | 2022-06-10actual | — | 2025-04-13 |
| A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult VolunteersNCT05213728Rate of Solicited Symptoms of ReactogenicityOpen-label · Prevention | Phase 1 | Completed | Biological: VXA-G1.1-NN | Norovirus Infections | 8 | 2022-02-01actual | — | 2024-06-21 |
| Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus VaccineNCT04854746Rate of Solicited Adverse EventsRandomized · Double-masked · Prevention | Phase 1 | Completed | Biological: VXA-GI.1.NN, Placebo Tablet | Norovirus Infections | 66 | 2022-01-04actual | — | 2023-02-13 |
| Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus VaccinesNCT04875676results2024-05-22Viral-capsid Protein 1 (VP1)-Specific Antibody Secreting Cells (ASC) by Enzyme-linked Immunospot (ELISpot) AssayNon-randomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: VXA-G1.1-NN | Norovirus Infections | 30 | 2021-10-30actual | — | 2024-05-22 |
| Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of SubjectsNCT04563702Frequency of solicited symptoms of reactogenicityNon-randomized · Open-label · Prevention | Phase 1 | Completed | Biological: VXA-CoV2-1 | Covid19 | 35 | 2021-10-10actual | — | 2024-06-21 |
| Safety & Immunogenicity Study of Ad5 Based Oral Norovirus VaccinesNCT03897309Rate of Solicited Adverse EventsRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets | Norovirus Infection | 86 | 2021-01-15actual | — | 2022-09-21 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma PatientsNCT02724254Percentage of patients with at least one local skin reaction (LSR)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AP611074 5% gel, AP611074 matching placebo | Condyloma | 218 | May 2018actual | — | 2018-07-20 |
| A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu VaccineNCT02918006results2022-10-06Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza VirusRandomized · Quadruple-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: VXA-A1.1, Fluzone® · Other: Placebo Tablets, Saline Solution for Placebo IM Injection | Influenza | 179 | 2017-08-08actual | — | 2022-10-06 |
| Dose-Optimization Trial of VXA-G1.1-NN in Healthy VolunteersNCT03125473Evaluate the safety of different dosing regimens of VXA-G1.1-NN vaccine as determined by the incidence of treatment-emergent adverse events, physical exams, vital signs, and clinical laboratory test results (hematology, serum chemistry, and urinalysis).Randomized · Open-label · Prevention | Phase 1 | Completed | Biological: VXA-G1.1-NN Oral Vaccine | Norovirus Gastroenteritis | 66 | 2017-07-01actual | — | 2018-05-30 |
| Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy AdultsNCT03121339PD: Location of disintegrationRandomized · Open-label · Other | Phase 1 | Completed | Biological: VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large) | Seasonal Influenza Preventative Vaccine Pharmacodynamics | 8 | 2017-05-05actual | — | 2018-05-30 |
| A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus InfectionNCT03024177Efficacy: Time-weighted average change from baseline to end of treatment visit in HRV viral load (HRV-RNA log10 copies/mL)Randomized · Triple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study is withdrawn due to company decision | Drug: Vapendavir, Placebo Oral Tablet | Rhinovirus, Upper Respiratory Tract Infection | 0 | Apr 2017actual | — | 2018-05-07 |
| Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy AdultsNCT02547792Safety and Tolerability of Single High Dose of an Oral Influenza B Tablet VaccineRandomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose) Oral Vaccine · Other: Placebo Tablets | Seasonal Influenza B | 54 | 2016-11-21actual | — | 2018-05-31 |
| Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus VaccineNCT02868073Incidence of Treatment Emergent Solicited and Unsolicited Adverse EventsRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA-G1.1-NN (low dose) Oral Vaccine Tablet · Other: VXA Placebo Tablets | Norovirus Gastroenteritis | 66 | 2016-10-05actual | — | 2018-05-31 |
| Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)NCT02830932Systemic Reactogenicity of VXA-RSV-f vaccine delivered by oral enteric tablet.Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: VXA-RSV-f Tablets (high dose), VXA-RSV-f Tablets (low dose) · Other: VXA Placebo Tablets | Respiratory Syncytial Virus (RSV) | 66 | 2016-09-16actual | — | 2018-08-16 |
| Immunogenicity of Seasonal Influenza by Delivery Directly to IleumNCT01761123SafetyOpen-label · Prevention | Phase 1 | Completed | Biological: VXA-A1.1 | Seasonal Influenza | 37 | Oct 2014actual | — | 2014-12-10 |
| Safety Study of an Oral Vaccine to Prevent Seasonal InfluenzaNCT01688297Safety of an oral vaccine tablet as measured by reported solicited (reactogenicity) and unsolicited adverse eventsRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: VXA-A1.1 Oral Vaccine, VXA Placebo Tablet | Influenza | 61 | May 2014actual | — | 2017-05-12 |
| Immunogenicity of ND1.1 by Delivery Directly to the IleumNCT01698060SafetyNon-randomized · Open-label · Prevention | Phase 1 | Completed | Biological: ND1.1 | Avian Influenza | 12 | Nov 2013actual | — | 2014-12-10 |
| Safety Study of an Oral Vaccine to Prevent Avian InfluenzaNCT01335347Frequency or severity of vaccine related events as measured through reported AEsRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: ND1.1, Placebo control | Avian Influenza, Bird Flu | 54 | Aug 2012actual | — | 2013-01-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19